Background Immunoglobulin E (IgE) binds to high affinity receptor FcεRI numerously expressed on mast cells. Recent findings have revealed that IgE by itself may regulate various aspects of mast cell biology, however, detailed data is still limited. Methodology/Findings Here, we have examined the influence of IgE alone, used at different concentrations, on mast cell activity and releasability. For the study we have employed in vivo differentiated mature tissue mast cells isolated from rat peritoneal cavity. Mast cells were exposed to IgE alone and then the release of preformed and de novo-synthesized mediators, surface FcεRI expression and mast cell migratory response were assessed. IgE by itself was found to up-regulate FcεRI expression and activate mast cells to degranulation, as well as de novo synthesis and release of cysteinyl leukotrienes and TNF. We have provided evidence that IgE alone also amplified spontaneous and CCL5- or TNF-induced migration of mast cells. Importantly, IgE was effective only at concentrations ≥ 3 μg/mL. A molecular basis investigation using an array of specific inhibitors showed that Src kinases, PLC/PLA2, MAP kinases (ERK and p38) and PI3K were entirely or partially involved in IgE-induced mast cell response. Furthermore, IgE alone stimulated the phosphorylation of MAP kinases and PI3K in rat mast cells. Conclusion Our results clearly demonstrated that IgE by itself, at higher concentrations, influences mast cell activity and releasability. As there are different conditions when the IgE level is raised it might be supposed that in vivo IgE is one of the important factors modulating mast cell biology within tissues.
References
[1]
Stone KD, Prussin C, Metcalfe DD (2010) IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 125: 73–80.
[2]
Gould HJ, Sutton BJ, Beavil AJ, Beavil RL, McCloskey N, et al. (2003) The biology of IgE and the basis of allergic disease. Annu Rev Immunol 21: 579–628.
[3]
Watanabe N, Bruschi F, Korenaga M (2005) IgE: a question of protective immunity in Trichinella spiralis infection. Trends Parasitol 21: 175–178.
[4]
Heimall J, Freeman A, Holland SM (2010) Pathogenesis of hyper IgE syndrome. Clin Rev Allergy Immunol 38: 32–38.
[5]
Freeman AF, Holland SM (2008) The hyper-IgE syndromes. Immunol Allergy Clin North Am 28: 277–291.
[6]
Ozcan E, Notarangelo LD, Geha RS (2008) Primary immune deficiencies with aberrant IgE production. J Allergy Clin Immunol 122: 1054–1062.
[7]
Ellis AK, Waserman S (2009) Hodgkin's lymphoma presenting with markedly elevated IgE: a case report. Allergy Asthma Clin Immunol 5: 12.
[8]
Koutsonikolis A, Day N, Chamizo W, Good RA, Kornfeld SJ (1997) Asymptomatic lymphoma associated with elevation of immunoglobulin E. Ann Allergy Asthma Immunol 78: 27–28.
[9]
Borish L, Dishuck J, Cox L, Mascali JJ, Williams J, et al. (1993) Sezary syndrome with elevated serum IgE and hypereosinophilia: role of dysregulated cytokine production. J Allergy Clin Immunol 92: 123–131.
[10]
Neuber K, Berg-Drewniock B, Volkenandt M, Neumaier M, Zeller W, et al. (1996) B-cell chronic lymphocytic leukemia associated with high serum IGE levels and pruriginous skin lesions: successful therapy with IFN-α 2b after failure on IFN-γ. Dermatology 192: 110–115.
[11]
Zar HJ, Latief Z, Hughes J, Hussey G (2002) Serum immunoglobulin E levels in human immunodeficiency virus-infected children with pneumonia. Pediatr Allergy Immunol 13: 328–333.
[12]
Marone G, Florio G, Triggiani M, Petraroli A, de Paulis A (2000) Mechanisms of IgE elevation in HIV-1 infection. Crit Rev Immunol 20: 477–496.
[13]
Wright DN, Nelson RP Jr, Ledford DK, Fernandez-Caldas E, Trudeau WL, et al. (1990) Serum IgE and human immunodeficiency virus (HIV) infection. J Allergy Clin Immunol 85: 445–452.
[14]
Chang CC, Lau YL (1991) Serum IgE levels in the convalescent phase of Kawasaki disease: a correlation with atopy? Pediatr Asthma Allergy Immunol 5: 253–258.
[15]
Ovcina-Kurtovic N, Kasumagic-Halilovic E (2010) Serum levels of total immunoglobulin E in patients with psoriasis: relationship with clinical type of disease. Med Arh 64: 28–29.
[16]
Schuerwegh AJ, Ioan-Facsinay A, Dorjée AL, Roos J, Bajema IM, et al. (2010) Evidence for a functional role of IgE anticitrullinated protein antibodies in rheumatoid arthritis. Proc Natl Acad Sci USA 107: 2586–2591.
[17]
Suurmond J, Schuerwegh AJ, Toes RE (2011) Anti-citrullinated protein antibodies in rheumatoid arthritis: a functional role for mast cells and basophils? Ann Rheum Dis 70: 55–58.
[18]
Iwata Y, Komura K, Kodera M, Usuda T, Yokoyama Y, et al. (2008) Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Arch Dermatol 144: 41–48.
[19]
Metz M, Maurer M (2007) Mast cells-key effector cells in immune responses. Trends Immunol 28: 234–241.
[20]
Rao KN, Brown MA (2008) Mast cells: multifaceted immune cells with diverse roles in health and disease. Ann NY Acad Sci 1143: 83–104.
[21]
Weller CL, Collington SJ, Williams T, Lamb JR (2011) Mast cells in health and disease. Clin Sci 120: 473–484.
[22]
Asai K, Kitaura J, Kawakami Y, Yamagata N, Tsai M, et al. (2001) Regulation of mast cell survival by IgE. Immunity 14: 791–800.
[23]
Borkowski TA, Jouvin MH, Lin SY, Kinet JP (2001) Minimal requirements for IgE-mediated regulation of surface FcεRI. J Immunol 167: 1290–1296.
[24]
Yamaguchi M, Sayama K, Yano K, Lantz CS, Noben-Trauth N, et al. (1999) IgE enhances FcεRI expression and IgE-dependent release of histamine and lipid mediators from human umbilical cord blood-derived mast cells: synergistic effect of IL-4 and IgE on human mast cell FcεRI expression and mediator release. J Immunol 162: 5455–5465.
[25]
Kubo S, Matsuoka K, Taya C, Kitamura F, Takai T, et al. (2001) Drastic up-regulation of FcεRI on mast cells is induced by IgE binding through stabilization and accumulation of FcεRI on the cell surface. J Immunol 167: 3427–3434.
[26]
Kalesnikoff J, Huber M, Lam V, Damen JE, Zhang J, et al. (2001) Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival. Immunity 14: 801–811.
[27]
Kohno M, Yamasaki S, Tybulewicz VL, Saito T (2005) Rapid and large amount of autocrine IL-3 production is responsible for mast cell survival by IgE in the absence of antigen. Blood 105: 2059–2065.
[28]
Kitaura J, Song J, Tsai M, Asai K, Maeda-Yamamoto M, et al. (2003) Evidence that IgE molecules mediate a spectrum of effects on mast cell survival and activation via aggregation of the FcεRI. Proc Natl Acad Sci USA 100: 12911–12916.
[29]
Cruse G, Cockerill S, Bradding P (2008) IgE alone promotes human lung mast cell survival through the autocrine production of IL-6. BMC Immunol 9: 2.
[30]
Lam V, Kalesnikoff J, Lee CW, Hernandez-Hansen V, Wilson BS, et al. (2003) IgE alone stimulates mast cell adhesion to fibronectin via pathways similar to those used by IgE + antigen but distinct from those used by Steel factor. Blood 102: 1405–1413.
[31]
Kitaura J, Kinoshita T, Matsumoto M, Chung S, Kawakami Y, et al. (2005) IgE- and IgE+Ag-mediated mast cell migration in an autocrine/paracrine fashion. Blood 105: 3222–3229.
[32]
Tanaka S, Mikura S, Hashimoto E, Sugimoto Y, Ichikawa A (2005) Ca2+ influx-mediated histamine synthesis and IL-6 release in mast cells activated by monomeric IgE. Eur J Immunol 35: 460–468.
[33]
Cruse G, Kaur D, Yang W, Duffy SM, Brightling CE, et al. (2005) Activation of human lung mast cells by monomeric immunoglobulin E. Eur Respir J 25: 858–863.
[34]
Matsuda K, Piliponsky AM, Iikura M, Nakae S, Wang EW, et al. (2005) Monomeric IgE enhances human mast cell chemokine production: IL-4 augments and dexamethasone suppresses the response. J Allergy Clin Immunol 116: 1357–1363.
[35]
Tanaka S, Takasu Y, Mikura S, Satoh N, Ichikawa A (2002) Antigen-independent induction of histamine synthesis by immunoglobulin E in mouse bone marrow-derived mast cells. J Exp Med 196: 229–235.
[36]
Brzezińska-B？aszczyk E, Pietrzak A, Misiak-T？oczek AH (2007) Tumor necrosis factor (TNF) is a potent rat mast cell chemoattractant. J Interferon Cytokine Res 27: 911–919.
[37]
Misiak-T？oczek A, Brzezińska-B？aszczyk E (2009) IL-6, but not IL-4, stimulates chemokinesis and TNF stimulates chemotaxis of tissue mast cells: involvement of both mitogen-activated protein kinases and phosphatidylinositol 3-kinase signalling pathways. APMIS 117: 558–567.
[38]
Juremalm M, Olsson N, Nilsson G (2002) Selective CCL5/RANTES-induced mast cell migration through interactions with chemokine receptors CCR1 and CCR4. Biochem Biophys Res Commun 297: 480–485.
[39]
Wierzbicki M, Brzezińska-B？aszczyk E (2009) Diverse effects of bacterial cell wall components on mast cell degranulation, cysteinyl leukotriene generation and migration. Microbiol Immunol 53: 694–703.
[40]
Ishizuka T, Okajima F, Ishiwara M, Iizuka K, Ichimonji I, et al. (2001) Sensitized mast cells migrate toward the antigen: a response regulated by p38 mitogen-activated protein kinase and Rho-associated coiled-coil-forming protein kinase. J Immunol 167: 2298–2304.
[41]
Roth K, Chen WM, Lin TJ (2008) Positive and negative regulatory mechanisms in high-affinity IgE receptor-mediated mast cell activation. Arch Immunol Ther Exp 56: 385–399.
[42]
Huber M, Helgason CD, Damen JE, Liu L, Humphries RK, et al. (1998) The src homology 2-containing inositol phosphatase (SHIP) is the gatekeeper of mast cell degranulation. Proc Natl Acad Sci USA 95: 11330–11335.
[43]
Kraft S, Kinet JP (2007) New developments in FcεRI regulation, function and inhibition. Nat Rev Immunol 7: 365–378.
[44]
Vasudev M, Cheung DS, Pincsak H, Li SH, Yan K, et al. (2012) Expression of high-affinity IgE receptor on human peripheral blood dendritic cells in children. PLoS One 7: e32556.
[45]
Kawakami T, Galli SJ (2002) Regulation of mast-cell and basophil function and survival by IgE. Nat Rev Immunol 2: 773–786.
